top of page
Search

What Are the Dangers of Taking Semaglutide? A Science-Based Safety Guide

Semaglutide (commonly prescribed as Ozempic for type 2 diabetes and Wegovy for chronic weight management) is a GLP-1 receptor agonist that can improve blood sugar control and support significant weight loss for many people. But “effective” doesn’t mean “risk-free.” If you’re considering semaglutide, or you’re already taking it, understanding the most important safety risks, warning signs, and who should be extra cautious can help you make smarter decisions with your medical team.


This article breaks down the real dangers of semaglutide, based on trusted clinical trials, FDA labeling, and peer-reviewed literature.



Quick definition: what semaglutide does in the body

Semaglutide works by mimicking the hormone GLP-1, which can:

  • increase insulin release when glucose is elevated

  • reduce glucagon (a hormone that raises blood sugar)

  • slow stomach emptying (gastric emptying)

  • reduce appetite and increase fullness


That last point, slower gastric emptying + appetite suppression is a major reason weight loss can happen… and also a reason several key risks exist.


The most important dangers of taking semaglutide

1) Thyroid C-cell tumor warning (boxed warning)

FDA-approved semaglutide products carry a boxed warning about thyroid C-cell tumors observed in rodents. It’s unknown whether semaglutide causes these tumors in humans, but the warning is still taken seriously.


Who should avoid semaglutide entirely (contraindicated):

  • anyone with a personal or family history of medullary thyroid carcinoma (MTC)

  • anyone with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)


Red-flag symptoms to report immediately:

  • a neck lump/swelling, hoarseness, trouble swallowing, or shortness of breath


2) Severe gastrointestinal side effects (and dehydration complications)

The most common side effects are gastrointestinal - often dose-related and most noticeable during dose escalation:

  • nausea, vomiting, diarrhea, constipation, abdominal pain


For some people these effects become severe, leading to dehydration and downstream problems (including kidney injury).


Why this matters: persistent vomiting/diarrhea + reduced fluid intake can cause volume depletion, dizziness/fainting, and electrolyte issues, and can snowball into urgent care visits.


3) Acute kidney injury (often linked to dehydration)

Semaglutide has been associated with acute kidney injury, including postmarketing reports with severe cases. The FDA labeling emphasizes risk especially when GI side effects lead to fluid loss.

Higher-risk situations:

  • older adults

  • chronic kidney disease

  • prolonged vomiting/diarrhea

  • not keeping up with fluids during dose increases


What to watch for:

  • very low urine output, dark urine, unusual fatigue, confusion, swelling, or persistent dizziness


4) Gallbladder disease (gallstones and gallbladder inflammation)

Clinical trial safety data show higher rates of gallbladder-related events with semaglutide compared with placebo, including gallstones (cholelithiasis). Rapid weight loss itself can also increase gallstone risk.


Warning signs:

  • right upper abdominal pain (especially after fatty meals)

  • nausea/vomiting with pain

  • fever

  • yellowing of skin/eyes (jaundice)


5) Pancreatitis (inflammation of the pancreas)

Acute pancreatitis has been observed in clinical trials and is an important “stop and evaluate” risk with GLP-1 medications.

Classic symptoms:

  • severe, persistent upper abdominal pain (may radiate to the back)

  • pain with vomiting that doesn’t resolve


If pancreatitis is suspected, this is not a “wait and see” situation - seek medical care.


6) Intestinal blockage/ileus and severe constipation (rare but serious)

FDA labeling for semaglutide includes post-approval reports of serious GI issues such as:

  • ileus

  • intestinal obstruction

  • severe constipation (including fecal impaction)


These events are uncommon, but they can be dangerous.

Urgent symptoms:

  • severe abdominal pain/distension

  • inability to pass stool or gas

  • persistent vomiting


7) Gastroparesis and delayed gastric emptying (and anesthesia aspiration risk)

Because semaglutide slows gastric emptying, some people experience clinically significant delayed stomach emptying, and case reports describe rare but serious complications.


This has also created a safety issue for procedures requiring anesthesia or deep sedation: delayed gastric emptying can increase risk of regurgitation and pulmonary aspiration.


What to do if you have a procedure coming up:

  • Tell your surgeon/anesthesia team you take a GLP-1 medication.

  • Guidance has evolved: earlier recommendations leaned toward holding GLP-1s pre-procedure, while later multi-society guidance emphasizes individualized risk assessment (for example, higher concern during dose escalation or with active GI symptoms).


8) Hypoglycemia (especially when combined with insulin or sulfonylureas)

Semaglutide alone does not usually cause low blood sugar in people without other glucose-lowering meds. The bigger danger is when semaglutide is used with:

  • insulin

  • sulfonylureas (or other insulin secretagogues)


Symptoms of hypoglycemia:

  • shaking, sweating, confusion, rapid heartbeat, weakness, blurred vision

Medication adjustment is often needed when semaglutide is added.


9) Diabetic retinopathy complications (important for people with diabetes)

In a major cardiovascular outcomes trial, semaglutide was associated with more diabetic retinopathy complications than placebo, particularly early on in some patients. One plausible contributor is rapid improvement in blood sugar (which can transiently worsen retinopathy risk in some cases).


If you have diabetes:

  • keep eye exams current

  • tell your clinician if you notice vision changes (blurred vision, floaters, sudden vision loss)


10) Mood changes and suicidal ideation warnings (weight management indication)

For Wegovy (weight management), labeling includes warnings related to suicidal behavior and ideation (not unique to semaglutide - seen across weight management products and monitored closely).

If you have a history of depression, anxiety, or suicidal ideation, this is a crucial discussion with your prescriber before starting.


11) Allergic reactions (rare but serious)

Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) are rare but possible.

Emergency symptoms:

  • swelling of face/lips/tongue, difficulty breathing, widespread hives


A danger that isn’t “the drug”: compounded or counterfeit semaglutide

Because demand is high, a major modern risk is people obtaining semaglutide outside legitimate channels:

  • counterfeit products entering supply chains

  • unapproved products sold online “for research use”

  • compounded versions with dosing errors or questionable ingredients/quality


The FDA has issued multiple warnings and alerts about:

  • counterfeit Ozempic found in the U.S. supply chain

  • dosing errors associated with compounded semaglutide injectables

  • unapproved GLP-1 products sold illegally and directly to consumers


Bottom line: Getting semaglutide from non-licensed sources can dramatically increase risk - independent of the medication’s inherent side effects.


Who should be extra cautious before taking semaglutide?

Semaglutide isn’t automatically “unsafe” in these situations, but risk-benefit needs closer review:

  • History of MTC or MEN2 (typically avoid)

  • History of pancreatitis

  • Gallbladder disease or prior gallstones

  • Severe GERD, known gastroparesis, or major GI motility issues

  • Chronic kidney disease, or frequent dehydration risk

  • Diabetic retinopathy

  • People in active dose escalation (side effects are often strongest here)

  • Upcoming surgery/procedure with anesthesia

  • History of severe depression or suicidal ideation (especially for weight loss use)


Safer results: the “medication + lifestyle” approach (where many people win)

One of the biggest long-term dangers with semaglutide isn’t a rare side effect - it’s regaining weight after stopping, especially if muscle mass, daily movement, nutrition habits, and strength training weren’t built alongside the medication.

A smart strategy many clinicians emphasize:

  • build sustainable nutrition routines (protein, fiber, hydration)

  • strength train to protect muscle

  • increase non-exercise activity (daily steps)

  • progress conditioning safely


This doesn’t replace medical care - but it can meaningfully reduce complications like frailty, poor energy, and rebound weight gain.


FAQ: Common questions about semaglutide dangers

Is semaglutide dangerous for everyone?

  • No. Many people tolerate it well. The key is that the risk profile varies by personal history, dose changes, other medications, and how it’s obtained/monitored.


What’s the most common problem people run into?

  • GI side effects - especially nausea, constipation, or diarrhea, often during dose escalation.


What side effects mean I should call my doctor urgently?

  • Severe abdominal pain (pancreatitis/gallbladder), persistent vomiting with dehydration, signs of intestinal obstruction, allergic reaction symptoms, or major mood changes.


Is it safe to buy semaglutide online?

  • Only if it’s dispensed by a legitimate, state-licensed pharmacy with a valid prescription. FDA warnings about counterfeit/unapproved products are a major reason to avoid unofficial sellers.


Call to action: Want safe, sustainable fat loss in Grand Prairie, without wrecking your energy?

Whether you’re considering semaglutide, currently using it, or trying to lose weight without medication, the foundation is the same: strength training, smart conditioning, and a realistic plan you can stick to.


If you’re in Grand Prairie, TX, the AqilFitness Training Solutions team can help you build a customized plan that supports fat loss while protecting muscle, performance, and long-term health.

  • 1-on-1 personal training

  • structured strength + conditioning programs

  • accountability and progression tracking

  • lifestyle coaching that actually fits your schedule


Reply with your goal (weight loss, strength, endurance, or “I just want to feel better”) and I’ll help you map out the right next step.


References

  1. U.S. Food and Drug Administration. Ozempic (semaglutide) injection – Prescribing Information (latest labeling PDF).

  2. U.S. Food and Drug Administration. Wegovy (semaglutide) injection – Prescribing Information (latest labeling PDF).

  3. Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine. 2016.

  4. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.

  5. Vilsbøll T, et al. Semaglutide, HbA1c reduction and risk of diabetic retinopathy complications (analysis of SUSTAIN program). Diabetes, Obesity and Metabolism. 2018.

  6. Kushner RF, et al. Safety profile of semaglutide vs placebo in the SELECT trial (2.4 mg). Obesity. 2025.

  7. American Society of Anesthesiologists. Consensus-Based Guidance on Preoperative Management of Patients on GLP-1 Receptor Agonists. 2023.

  8. American Society of Anesthesiologists. Multi-society GLP-1 guidance news release (perioperative use). 2024.

  9. U.S. Food and Drug Administration. FDA alerts on dosing errors with compounded semaglutide. 2024.

  10. U.S. Food and Drug Administration. FDA warns consumers not to use counterfeit Ozempic found in U.S. drug supply chain. Updated 2025.

  11. U.S. Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss. 2025.

  12. Chaudhry A, et al. Semaglutide-induced gastroparesis case report. 2024.



Related Articles:

Comments

bottom of page